Current Pharmaceutical Biotechnology

Author(s): Yuechi Sun, Yan He, Yuan Liu and Guixiu Shi

DOI: 10.2174/138920101506140910145940

Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease

Page: [521 - 524] Pages: 4

  • * (Excluding Mailing and Handling)

Abstract

Interstitial lung disease (ILD) is one of the most common complications of polymyositis (PM) and dermatomyositis (DM). It is always progressive and does not respond to conventional immunosuppressive agent treatment. Biologics are commonly used in treatment of rheumatic diseases. They are also used in polymyositis and dermatomyositis associated interstitial lung disease. This review will focus on the updated use of biologics in PM/DM-ILD.

Keywords: Biologics, dermatomyositis, interstitial lung disease, polymyositis.